Tricyclodecan-9-yl-Xanthogenate (D609): Mechanism of Action and Pharmacological Applications
- PMID: 35328726
- PMCID: PMC8954530
- DOI: 10.3390/ijms23063305
Tricyclodecan-9-yl-Xanthogenate (D609): Mechanism of Action and Pharmacological Applications
Abstract
Tricyclodecan-9-yl xanthogenate (D609) is a synthetic tricyclic compound possessing a xanthate group. This xanthogenate compound is known for its diverse pharmacological properties. Over the last three decades, many studies have reported the biological activities of D609, including antioxidant, antiapoptotic, anticholinergic, anti-tumor, anti-inflammatory, anti-viral, anti-proliferative, and neuroprotective activities. Its mechanism of action is extensively attributed to its ability to cause the competitive inhibition of phosphatidylcholine (PC)-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). The inhibition of PCPLC or SMS affects secondary messengers with a lipidic nature, i.e., 1,2-diacylglycerol (DAG) and ceramide. Various in vitro/in vivo studies suggest that PCPLC and SMS inhibition regulate the cell cycle, block cellular proliferation, and induce differentiation. D609 acts as a pro-inflammatory cytokine antagonist and diminishes Aβ-stimulated toxicity. PCPLC enzymatic activity essentially requires Zn2+, and D609 might act as a potential chelator of Zn2+, thereby blocking PCPLC enzymatic activity. D609 also demonstrates promising results in reducing atherosclerotic plaque formation, post-stroke cerebral infarction, and cancer progression. The present compilation provides a comprehensive mechanistic insight into D609, including its chemistry, mechanism of action, and regulation of various pharmacological activities.
Keywords: cellular proliferation; ceramide; pharmacological properties; tricyclodecan-9-yl xanthogenate (D609).
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Multiple activities of sphingomyelin synthase 2 generate saturated fatty acid- and/or monounsaturated fatty acid-containing diacylglycerol.J Biol Chem. 2024 Dec;300(12):107960. doi: 10.1016/j.jbc.2024.107960. Epub 2024 Nov 5. J Biol Chem. 2024. PMID: 39510177 Free PMC article.
-
Tricyclodecan-9-yl-xanthogenate (D609) mechanism of actions: a mini-review of literature.Neurochem Res. 2012 Apr;37(4):671-9. doi: 10.1007/s11064-011-0659-z. Epub 2011 Nov 22. Neurochem Res. 2012. PMID: 22101393 Free PMC article. Review.
-
Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.Mol Neurobiol. 2012 Jun;45(3):455-64. doi: 10.1007/s12035-012-8254-0. Epub 2012 Mar 14. Mol Neurobiol. 2012. PMID: 22415444 Free PMC article.
-
Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells.Neuroscience. 2007 May 25;146(3):946-61. doi: 10.1016/j.neuroscience.2007.02.022. Epub 2007 Apr 16. Neuroscience. 2007. PMID: 17434680 Free PMC article.
-
Priming of alveolar macrophage respiratory burst by H(2)O(2) is prevented by phosphatidylcholine-specific phospholipase C inhibitor Tricyclodecan-9-yl-xanthate (D609).J Pharmacol Exp Ther. 2002 Apr;301(1):87-94. doi: 10.1124/jpet.301.1.87. J Pharmacol Exp Ther. 2002. PMID: 11907161
Cited by
-
D609 Suppresses Antituberculosis Response by Regulating Dendritic Cells Antigen Presentation.Immun Inflamm Dis. 2024 Dec;12(12):e70103. doi: 10.1002/iid3.70103. Immun Inflamm Dis. 2024. PMID: 39692711 Free PMC article.
-
Multiple activities of sphingomyelin synthase 2 generate saturated fatty acid- and/or monounsaturated fatty acid-containing diacylglycerol.J Biol Chem. 2024 Dec;300(12):107960. doi: 10.1016/j.jbc.2024.107960. Epub 2024 Nov 5. J Biol Chem. 2024. PMID: 39510177 Free PMC article.
References
-
- Eurtivong C., Pilkington L.I., van Rensburg M., White R.M., Bar H.K., Rees S., Paulin E.K., Xu C.S., Sharma N., Leung I.K.H., et al. Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents. Eur. J. Med. Chem. 2020;187:111919. doi: 10.1016/j.ejmech.2019.111919. - DOI - PubMed
-
- Podo F., Paris L., Cecchetti S., Spadaro F., Abalsamo L., Ramoni C., Ricci A., Pisanu M.E., Sardanelli F., Canese R., et al. Activation of phosphatidylcholine-specific phospholipase C in breast and ovarian cancer: Impact on MRS-detected choline metabolic profile and perspectives for targeted therapy. Front. Oncol. 2016;6:171. doi: 10.3389/fonc.2016.00171. - DOI - PMC - PubMed
-
- Milhas D., Andrieu-Abadie N., Levade T., Benoist H., Ségui B. The tricyclodecan-9-yl-xanthogenate D609 triggers ceramide increase and enhances FasL-induced caspase-dependent and-independent cell death in T lymphocytes. Int. J. Mol. Sci. 2012;13:8834–8852. doi: 10.3390/ijms13078834. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources